Adam Betík

Adam Betík

Auto-generated profile, based on publicly available information

Adam Betík

Department of Neurology Masaryk University Brno Czechia

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2025 in European Journal of Neurology
Verified
Journal Article
Open access
LJLubica Joppekova
Lubica Joppekova
ABAdam Betík
Adam Betík
LBLucia Bakošová
Lucia Bakošová
ISIva Srotova
Iva Srotova
TRTomáš Rohan
Tomáš Rohan
JBJosef Bednarik
Josef Bednarik
Background: Asymptomatic degenerative cervical cord compression (ADCC) represents a premyelopathic stage of degenerative cervical myelopathy (DCM), with high prevalence in older age and unclear management. Contact heat‐evoked potentials (CHEPs) assess the integrity of the thermo‐algesic somatosensory pathway and have shown the highest sensitivity among neurophysiological methods in detecting dysfunction in the centromedial and anterior spinal cord in DCM. Methods: This cross‐sectional cohort study evaluated the utility of upper extremity dermatomal C4, C6 and C8 CHEPs (dCHEPs) compared to standard neurophysiological methods—median and tibial nerves somatosensory evoked potentials (SEPs), upper and lower extremity motor evoked potentials (MEPs), and electromyography (EMG)—for detecting subclinical cervical cord dysfunction in ADCC. Two cohorts were included: 82 ADCC patients (mean age 53.7 ± 9.8 years; 53 females) and 10 DCM patients (mean age 64.0 ± 7.9 years; 4 females). All underwent bilateral dCHEPs (C4, C6, C8), SEPs, MEPs, and EMG (C5–C8 myotomes). Results: dCHEPs abnormalities were found in 50% of ADCC patients, exceeding the rates for SEPs (32.1%), MEPs (21.8%), and EMG (13.9%). In 20.7%, dCHEPs were the only abnormal neurophysiological finding. In the DCM cohort, dCHEPs were abnormal in 80%, and were the only abnormality in 20%. In both groups, abnormalities were most frequent in the C8 dermatome. Conclusions: dCHEPs demonstrated superior sensitivity in detecting cervical cord dysfunction, not only in DCM but also in ADCC. As a functional complement to MRI, they may aid in identifying early spinal cord involvement. Their prognostic role in ADCC warrants further study.

19 August 2026 in European Journal of Neurology
Verified
Journal Article
Open access
PDF file
MKMagui Khazaal
Magui Khazaal
PSPaula Stretavská
Paula Stretavská
MKMagdalena Kuźma‐Kozakiewicz
Magdalena Kuźma‐Kozakiewicz
KNKrzysztof NieporęCki
Krzysztof NieporęCki
ABAdam Betík
Adam Betík
LSLenka Slachtova
Lenka Slachtova
Background: Amyotrophic lateral sclerosis (ALS) is one of the most devastating fatal motor neuron diseases, characterized by progressive degeneration of motor neurons in the brain and spinal cord. A significant advance in ALS therapy was achieved with the recent European Medicines Agency approval of Tofersen, the first antisense oligonucleotide (ASO) specifically targeting SOD1 mRNA, a key genetic determinant of the disease. Yet, despite its clinical relevance, data on SOD1 ‐ALS in Central Eastern Europe remain scarce. Methods: Here, we present a multicentric study across six countries—Austria, Czechia, Poland, Hungary, Slovakia, and Slovenia—representing approximately 16% of the European Union's population. We report all pathogenic, likely pathogenic, and uncertain SOD1 variants, along with the phenotypic features, including heritability, age, site of onset, and survival. We also assessed the availability of genetic testing, counseling, and access to Tofersen therapy across the region. Results: Out of 1200 patients with confirmed ALS, we identified 24 distinct pathogenic SOD1 variants in a total of 67 patients (median age at onset 47 [40–55] years), of whom 65.7% had familial ALS (fALS) and 34.3% had sporadic ALS (sALS). We characterized the associated phenotypes and reported that 42 patients are currently receiving Tofersen therapy. Conclusion: This study provides the first comprehensive overview of SOD1 ‐ALS in Central Eastern Europe. Our findings underscore the importance of genetic testing and counseling, as well as equitable access to targeted therapies such as Tofersen to advance patient‐specific care in this region.